|Address||107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Korea|
Green Cross Laboratories (GC Labs) is a Korea’s leading clinical laboratory which provides clinical and anatomic pathology reference testing. GC Labs offer more than 4,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays. We continue to acquire the latest technology and machines for clinical testing with strong and open partnerships with world-class laboratories and institutions. With our clients, GC Labs will continue to expand beyond Korea to become a world-leading reference laboratory. Established in 2013, as a subsidiary of Green Cross, GC Genome is a leading company in the field of clinical genomic diagnostic service provider and the first CAP accredited laboratory in Korea as a non-medical institution incorporating about 100 employees with 7 medical doctors. Our key diagnostic areas include Precision Oncology, Hereditary/Rare diseases, Prenatal and Health screening. We will transform paradigm of healthcare industry by launching the first-in class test and providing the best-in class service.
GC Labs offer more than 4,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays. We continue to acquire the latest technology and machines for clinical testing with strong and open partnerships with world-class laboratories and institutions.
1. Solid Cancer NGS Panel - Definition The test analyzes genetic mutations associated with gastric cancer, liver cancer, thyroid cancer, pancreatic cancer, colon cancer, and other cancers that develop in solid organs from the patient’s cancer tissue to give information for using target therapy. - Advantage It provides TMB score and MSI status in order to guide the use of immunotherapy. 2. Hematologic Cancer NGS Panel - Definition The test observes and analyzes genetic mutations associated with hematologic cancer - Advantage It is possible to order additional IGH/IGK/TRB/TRG gene rearrangement test to identify minimal residual diseases of malignant B-cell/T-cell lymphocytic diseases and benign lymphocytic proliferative diseases. 3. Hereditary Cancer NGS Panel - Definition The test predicts the likelihood of a variety of hereditary cancers by analyzing the sequence of causal genes from the blood of the test - Advantage It can detect deep-intronic alteration to identify more pathogenic variants. 4. Liquid Biopsy NGS Panel - Definition The test detects cell-free circulating tumor DNA (ctDNA) in blood specimens of advanced solid-tumor cancer patient. It tests major alterations relevant for treatment selection: point mutations, indels (insertions/deletions), copy number amplifications, fusions/rearrangements and chromosome instability. - Advantage It is possible to detect clinically relevant alterations via a simple blood draw. 5. HRD Test - Definition his assay uses next generation sequencing (NGS) technology to detect homologous recombination deficiency based on analysis of genomic instability and BRCA1/BRCA2 gene mutation. In tumor cells, the DNA damage is not properly repaired and the cell continues to divide. A case in which DNA repair process does not occur due to problem in homologous recombination function or mutation in BRCA gene is referred to as Homologous Recombination Deficiency (HRD). Tumors with HRD are particularly susceptible to specific targeted cancer therapies such as the PARP inhibitors.